Possible applications for dopaminergic agents following traumatic brain injury: part 2.
Zafonte
R D
RD
Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, Pennsylvania 15213-3221, USA.
Lexell
J
J
Cullen
N
N
D000547:Amantadine / Q000627:therapeutic use; D001577:Benzophenones / Q000627:therapeutic use; D052160:Benzothiazoles; D001930:Brain Injuries / Q000188:drug therapy*; D002396:Catechols / Q000627:therapeutic use; D015259:Dopamine Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use; D009570:Nitriles; D009596:Nitrophenols; D018579:Patient Selection; D000077487:Pramipexole; D012642:Selegiline / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D000077867:Tolcapone
D001577:Benzophenones; D052160:Benzothiazoles; D002396:Catechols; D015259:Dopamine Agents; D007211:Indoles; D018696:Neuroprotective Agents; D009570:Nitriles; D009596:Nitrophenols; D013844:Thiazoles; C046649:ropinirole; D012642:Selegiline; C071192:entacapone; D000077487:Pramipexole; D000547:Amantadine; D000077867:Tolcapone